Abstract

Hyporesponsiveness to erythropoiesis-stimulating agent (ESA) may be associated with protein-energy wasting. We investigated the relationship of the ESA resistance index (ERI) and the geriatric nutritional risk index (GNRI) for cardiovascular mortality in hemodialysis (HD) patients. A total of 180 maintenance HD patients were enrolled. The patients were stratified by the GNRI of 91.2, a previously reported cut-off value, and the ERI of 13.7 (IU/week/kg/g/dL), a cut-off value for predicting cardiovascular-specific mortality, and they were classified into four groups (group 1[G1]: higher GNRI and lower ERI, G2: higher GNRI and higher ERI, G3: lower GNRI and lower ERI, G4: lower GNRI and higher ERI). The ERI was independently associated with the GNRI (β = -0.271, p = 0.0005). During a median follow-up of 4.6 years, higher ERI and lower GNRI were independently associated with cardiovascular mortality, respectively (adjusted hazard ratio [aHR], 3.10; 95% confidence interval [CI], 1.31-7.34, and aHR, 6.64; 95%CI, 2.60-16.93, respectively). The 7-year survival rates were 96.1%, 70.3%, 77.3%, and 50.1% in G1, G2, G3, and G4, respectively. The aHR values for G4 versus G1 were 12.63 (95%CI, 3.58-44.59). With regards to model discrimination, adding the GNRI alone, the ERI alone, and both to the traditional risk model significantly improved the net reclassification improvement by 0.421, 0.662, and 0.671, respectively. Similar results were obtained for all-cause mortality. The ERI was independently associated with the GNRI, and could predict cardiovascular mortality in HD patients. Moreover, the combination of GNRI and ERI could improve the predictability for cardiovascular mortality.

Highlights

  • Renal anemia, which is caused by decreased erythropoietin production due to kidney injury, is common among patients undergoing hemodialysis (HD), and is treated with erythropoiesisstimulating agents (ESAs)

  • The ESA resistance index (ERI) was independently associated with the geriatric nutritional risk index (GNRI) (β = −0.271, p = 0.0005)

  • During a median follow-up of 4.6 years, higher ERI and lower GNRI were independently associated with cardiovascular mortality, respectively

Read more

Summary

Introduction

Renal anemia, which is caused by decreased erythropoietin production due to kidney injury, is common among patients undergoing hemodialysis (HD), and is treated with erythropoiesisstimulating agents (ESAs). It has been shown that HD patients who receive a high dose of ESAs relative to the hemoglobin (Hb) response experience poor outcomes, including increased risk of cardiovascular events or mortality[1,2,3]. It is not yet known whether these risks are caused by ESAs themselves, or underlying processes leading to increased ESA requirements. The ESA resistance index (ERI) has been proposed as an indicator for ESA hyporesponsiveness, and some previous studies have shown that the ERI can predict all-cause mortality and/or cardiovascular events[6,7,8]. The associations between the ERI and cardiovascular mortality remain unclear

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call